



#41048

DATE: **APRIL 27, 2017**

SUBJECT: **MAST THERAPEUTICS, INC. - REVERSE
SPLIT AND NAME/SYMBOL/CUSIP CHANGE
OPTION SYMBOL: MSTX
NEW SYMBOL: SVRA1
DATE: 04/28/17**

On April 27, 2017, Shareholders of Mast Therapeutics, Inc. (MSTX) voted concerning the proposed reverse split and merger with Savara Inc. The reverse split and merger were approved and consummated on April 27, 2017. As a result, Mast Therapeutics, Inc. will change its name, trading symbol and CUSIP to Savara Inc. (SVRA), CUSIP 805111101, and each share of MSTX Common Share will be converted into the right to receive 0.01428571 (New) SVRA Common Shares. Cash will be paid in lieu of fractional shares.

CONTRACT ADJUSTMENT

Effective Date: April 28, 2017

Option Symbol: MSTX changes to SVRA1

Contract Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

New Deliverable
Per Contract: 1) 1 (New) Savara Inc. (SVRA) Common Shares
2) Cash in lieu of approximately 0.428571 fractional SVRA Shares

CUSIP: SVRA (New): 805111101

PRICING

Until the cash in lieu amount is determined, the underlying price for SVRA1 will be determined as follows:

$$\text{SVRA1} = 0.01428571 (\text{SVRA})$$

DELAYED SETTLEMENT

The SVRA component of the SVRA1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the SVRA1 deliverable until the cash in lieu of fractional SVRA Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 25, or 25A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theoocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theoocc.com.